Chitosan nanoparticles functionalised with protocatechuic acid improve colon-targeted pazopanib delivery with multi-pathway therapeutic regulation and pharmacokinetic optimisation in colorectal cancer
Аннотация
Poor pharmacokinetics, insufficient tumor-selective drug accumulation, and systemic toxicity are often the main obstacles to colorectal cancer (CRC) treatment. Here, protocatechuic acid-functionalized chitosan nanoparticles (PAZ-CS-PCA-NPs) were designed to enhance the pharmacological efficacy of pazopanib via colon-targeted administration. Ionic gelation and EDC/NHS functionalization were used to create PAZ-CS-PCA-NPs, which were then assessed for hemocompatibility, pharmacokinetics, biodistribution, therapeutic efficacy, gut microbiota regulation, cognitive function, and safety in a rat model of colorectal cancer induced by dimethylhydrazine. After five hours, PAZ-CS-PCA-NPs showed less than 0.8% haemolysis and kept platelet aggregation at about 20% as opposed to more than 90% in the positive Control. With improved colonic accumulation, as verified by fluorescence imaging, subsequent to intraperitoneal delivery, the nanoformulation significantly reduced the T max from 8.0 ± 0.5 h to 0.5 ± 0.1 h and elevated the C max from 0.377 ± 0.024 to 0.553 ± 0.020 μg mL⁻ 1 . Treatment increased GPx-1 from 2.578 to 8.828 ng mL⁻ 1 , decreased LPO from 26.874 to 8.929 ng mL⁻ 1 , and lowered IL-6 from 472.6 to 36.59 ng mL⁻ 1 . Furthermore, PAZ-CS-PCA-NPs revealed no significant treatment-related organ histopathological changes during acute toxicity assessment, reduced Morris water maze escape latency from 113.6 s to 58 s, altered the abundance of selected cultivable fecal bacterial populations under the tested culture conditions, and provided a translational nanotherapeutic approach for targeted CRC therapy. Graphical abstract